Drug Patents Expiring in 2039

1. Drug name - AIRDUO DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653

(Pediatric)

TEVA PHARM Inhaler Jun, 2039

(16 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.113MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription
0.232MG/INH;EQ 0.014MG BASE/INH POWDER;INHALATION Prescription

2. Drug name - ANJESO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881663 BAUDAX Method of treating pain in elderly patients with mild renal impairment Mar, 2039

(16 years from now)

Drugs and Companies using MELOXICAM ingredient

Treatment: Management of moderate-to-severe pain by intravenous injection in patients with mild renal impairment

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
30MG/ML (30MG/ML) SOLUTION;INTRAVENOUS Prescription

3. Drug name - ANNOVERA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632066 THERAPEUTICSMD INC Method of providing birth control Feb, 2039

(16 years from now)

US10780047 THERAPEUTICSMD INC Method of providing birth control Feb, 2039

(16 years from now)

US10765628 THERAPEUTICSMD INC Method of providing birth control Feb, 2039

(16 years from now)

US10925882 THERAPEUTICSMD INC System for providing birth control Jun, 2039

(16 years from now)

US10918649 THERAPEUTICSMD INC System for providing birth control Jun, 2039

(16 years from now)

US10940157 THERAPEUTICSMD INC System for providing birth control Jun, 2039

(16 years from now)

Drugs and Companies using ETHINYL ESTRADIOL; SEGESTERONE ACETATE ingredient

Treatment: Method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception; method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; Method of preventing pregnancy by inserting a vaginal system containing 103 mg of segesterone acetate and 17.4 mg ethinyl estradiol into a vagina for up to thirteen 21/7-day (in/out) cycles; method of contraception by inserting a vaginal system for up to 13 21/7-day (in/out) cycles, wherein efficacy requires the system cannot be out of the vagina for more than 2 cumulative hours in any such cycle without using alternative contraception

Dosage: RING;VAGINAL

More Information on Dosage
Strength Dosage Availability
0.013MG/24HR;0.15MG/24HR RING;VAGINAL Prescription

4. Drug name - ARMONAIR DIGIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000653

(Pediatric)

TEVA PHARM Inhaler Jun, 2039

(16 years from now)

More Information on Dosage
Strength Dosage Availability
0.055MG/INH POWDER;INHALATION Discontinued
0.113MG/INH POWDER;INHALATION Discontinued
0.232MG/INH POWDER;INHALATION Discontinued
0.03MG/INH POWDER;INHALATION Discontinued

5. Drug name - BAQSIMI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765602 ELI LILLY AND CO Medication delivery systems and methods Sep, 2039

(16 years from now)

Drugs and Companies using GLUCAGON ingredient

Treatment: NA

Dosage: POWDER;NASAL

More Information on Dosage
Strength Dosage Availability
3MG POWDER;NASAL Prescription

6. Drug name - BYLVAY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10975046 ALBIREO Crystal modifications of odevixibat
Jun, 2039

(16 years from now)

Drugs and Companies using ODEVIXIBAT ingredient

Treatment: NA

Dosage: CAPSULE, PELLETS;ORAL; CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
0.2MG CAPSULE, PELLETS;ORAL Prescription
0.6MG CAPSULE, PELLETS;ORAL Prescription
0.4MG CAPSULE;ORAL Prescription
1.2MG CAPSULE;ORAL Prescription

7. Drug name - CAPLYTA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10695345 INTRA-CELLULAR Pharmaceutical capsule compositions comprising lumateperone mono-tosylate Aug, 2039

(16 years from now)

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

Treatment: Treatment of schizophrenia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 42MG BASE CAPSULE;ORAL Prescription

8. Drug name - DHIVY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11033521 AVION PHARMS Levodopa fractionated dose composition and use Mar, 2039

(16 years from now)

Drugs and Companies using CARBIDOPA; LEVODOPA ingredient

Treatment: Treatment of parkinson's disease; method of treating parkinson's disease by orally administering segments of a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg, each segment having carbidopa—6.25 mg/levodopa—25 mg; method of treating parkinson's disease by orally administering a functionally multiscored, bilayered tablet having carbidopa—25 mg/levodopa—100 mg

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
25MG;100MG TABLET;ORAL Prescription

9. Drug name - ELCYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10912795 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10905713 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10933089 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10918662 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10653719 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10905714 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10583155 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10478453 EXELA PHARMA Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/10ML (50MG/ML) SOLUTION;INTRAVENOUS Prescription

10. Drug name - EPIDIOLEX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11207292 GW RES LTD Cannabidiol preparations and its uses
Apr, 2039

(16 years from now)

Drugs and Companies using CANNABIDIOL ingredient

Treatment: NA

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
100MG/ML SOLUTION;ORAL Prescription

11. Drug name - INGREZZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11026931 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Aug, 2039

(16 years from now)

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Treatment: Treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription
EQ 60MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

12. Drug name - KATERZIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799453 AZURITY Amlodipine formulations Apr, 2039

(16 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 1MG BASE/ML SUSPENSION;ORAL Prescription

13. Drug name - LYVISPAH

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792262 AMNEAL Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives Jul, 2039

(16 years from now)

Drugs and Companies using BACLOFEN ingredient

Treatment: Method for treating spasticity

Dosage: GRANULES;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/PACKET GRANULES;ORAL Prescription
10MG/PACKET GRANULES;ORAL Prescription
20MG/PACKET GRANULES;ORAL Prescription

14. Drug name - NOURESS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10905713 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10933089 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10905714 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10653719 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10912795 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10918662 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10583155 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10478453 BAXTER HLTHCARE CORP Stable, highly pure L-cysteine compositions for injection and methods of use Jan, 2039

(16 years from now)

US10702490 BAXTER HLTHCARE CORP Cysteine composition and injection Mar, 2039

(16 years from now)

US10543186 BAXTER HLTHCARE CORP Cysteine composition and injection Mar, 2039

(16 years from now)

US10493051 BAXTER HLTHCARE CORP Cysteine composition and injection Mar, 2039

(16 years from now)

US11045438 BAXTER HLTHCARE CORP Cysteine composition and injection Mar, 2039

(16 years from now)

Drugs and Companies using CYSTEINE HYDROCHLORIDE ingredient

Treatment: Method of using l-cysteine in an admixture for treating patients needing parenteral nutrition; Method of intravenously administering a diluted cysteine hydrochloride solution to a neonate in need thereof

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
500MG/10ML (50MG/ML) SOLUTION;INTRAVENOUS Discontinued

15. Drug name - NURTEC ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11083724 BIOHAVEN IRELAND Rimegepant for CGRP related disorders Mar, 2039

(16 years from now)

Drugs and Companies using RIMEGEPANT SULFATE ingredient

Treatment: Acute treatment of migraine with or without aura in adults; preventive treatment of episodic migraine in adults

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 75MG BASE TABLET, ORALLY DISINTEGRATING;ORAL Prescription

16. Drug name - ORLADEYO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10662160 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor
Nov, 2039

(17 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11117867 BIOCRYST Crystalline salts of a plasma kallikrein inhibitor Nov, 2039

(17 years from now)

Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient

Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 110MG BASE CAPSULE;ORAL Prescription
EQ 150MG BASE CAPSULE;ORAL Prescription

17. Drug name - OZOBAX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610502 METACEL PHARMS LLC Oral baclofen solutions Aug, 2039

(16 years from now)

Drugs and Companies using BACLOFEN ingredient

Treatment: Treatment of spasticity

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/5ML SOLUTION;ORAL Prescription

18. Drug name - POTASSIUM PHOSPHATES

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10632150 CMP DEV LLC Potassium phosphates composition for injection Apr, 2039

(16 years from now)

Drugs and Companies using POTASSIUM PHOSPHATE, DIBASIC; POTASSIUM PHOSPHATE, MONOBASIC ingredient

Treatment: Potassium phosphates injection is indicated as a source of phosphorus in intravenous fluids to correct hypophosphatemia in adults and pediatric patients 12 years of age and older

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
4.5GM/15ML (300MG/ML);2.65GM/15ML (175MG/ML) SOLUTION;INTRAVENOUS Prescription

19. Drug name - QVAR REDIHALER

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10792447 NORTON WATERFORD Breath actuated inhaler Jan, 2039

(16 years from now)

Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient

Treatment: NA

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.04MG/INH AEROSOL, METERED;INHALATION Prescription
0.08MG/INH AEROSOL, METERED;INHALATION Prescription

20. Drug name - SOTALOL HYDROCHLORIDE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799138 ALTATHERA PHARMS LLC Method of administering sotalol IV/switch Apr, 2039

(16 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Treatment: Use for loading dose in patients with symptomatic afib/afl who are currently in sinus rhythm or for the treatment of life-threatening ventricular tachycardia

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage
Strength Dosage Availability
150MG/10ML (15MG/ML) SOLUTION;INTRAVENOUS Prescription

21. Drug name - TIBSOVO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10980788 SERVIER Therapy for treating malignancies Jun, 2039

(16 years from now)

Drugs and Companies using IVOSIDENIB ingredient

Treatment: A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; treating newly diagnosed acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
250MG TABLET;ORAL Prescription

22. Drug name - TRUDHESA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185497 IMPEL NEUROPHARMA Intranasal delivery of dihydroergotamine by precision olfactory device Jan, 2039

(16 years from now)

Drugs and Companies using DIHYDROERGOTAMINE MESYLATE ingredient

Treatment: Nasal administration of dihydroergotamine mesylate by metered spray for the acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.725MG/SPRAY SPRAY, METERED;NASAL Prescription

23. Drug name - UPNEEQ

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10799481 RVL PHARMS Compositions and methods for treating ocular disorders Dec, 2039

(17 years from now)

US10814001 RVL PHARMS Oxymetazoline compositions Dec, 2039

(17 years from now)

US10898573 RVL PHARMS Oxymetazoline compositions Dec, 2039

(17 years from now)

US11103482 RVL PHARMS Oxymetazoline compositions Dec, 2039

(17 years from now)

US10940138 RVL PHARMS Compositions and methods for treating ocular disorders Dec, 2039

(17 years from now)

Drugs and Companies using OXYMETAZOLINE HYDROCHLORIDE ingredient

Treatment: Method of treating blepharoptosis

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SOLUTION/DROPS;OPHTHALMIC Prescription

24. Drug name - VUITY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10610518 ABBVIE INC Presbyopia treatments Apr, 2039

(16 years from now)

Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient

Treatment: Use of vuity for the treatment of presbyopia in adults

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
1.25% SOLUTION;OPHTHALMIC Prescription

25. Drug name - XARELTO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828310 JANSSEN PHARMS Reducing the risk of cardiovascular events Jan, 2039

(16 years from now)

US10828310

(Pediatric)

JANSSEN PHARMS Reducing the risk of cardiovascular events Jul, 2039

(16 years from now)

Drugs and Companies using RIVAROXABAN ingredient

Treatment: Reduction of risk of cardiovascular death, myocardial infarction, and stroke in patients with cad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily; reduction of risk of myocardial infarction and ischemic stroke in patients with pad by administering clinically proven effective amounts that are 2.5 mg rivaroxaban twice daily and 75-100 mg aspirin daily

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription
15MG TABLET;ORAL Prescription
20MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.